Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants
NCT ID: NCT00152542
Last Updated: 2013-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
160 participants
INTERVENTIONAL
2005-05-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure
NCT00922532
Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure
NCT00016523
Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies
NCT00551642
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
NCT00006401
Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants
NCT01748045
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inhaled nitric oxide
Inhaled nitric oxide
1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
Placebo
Placebo
No iNO given for days 1-7
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inhaled nitric oxide
1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
Placebo
No iNO given for days 1-7
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
4 Years
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mallinckrodt
INDUSTRY
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael D Schreiber, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The University of Chicago, Comer Children's Hospital,
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Patrianakos-Hoobler AI, Marks JD, Msall ME, Huo D, Schreiber MD. Safety and efficacy of inhaled nitric oxide treatment for premature infants with respiratory distress syndrome: follow-up evaluation at early school age. Acta Paediatr. 2011 Apr;100(4):524-8. doi: 10.1111/j.1651-2227.2010.02077.x. Epub 2010 Dec 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29078
Identifier Type: -
Identifier Source: secondary_id
9549 (temp19)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.